about
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the rewardImpact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.Antiplatelet agents and proton pump inhibitors - personalizing treatment.Management of Coronary Artery Disease in South Asian Populations: Why and How to Prevent and Treat Differently.Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1 in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of Healthy Individuals.
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Clinical implications of aspirin resistance
@ast
Clinical implications of aspirin resistance
@en
Clinical implications of aspirin resistance
@nl
type
label
Clinical implications of aspirin resistance
@ast
Clinical implications of aspirin resistance
@en
Clinical implications of aspirin resistance
@nl
prefLabel
Clinical implications of aspirin resistance
@ast
Clinical implications of aspirin resistance
@en
Clinical implications of aspirin resistance
@nl
P2860
P356
P1476
Clinical implications of aspirin resistance
@en
P2093
Darshana Patel
Majaz Moonis
P2860
P304
P356
10.1586/14779072.5.5.969
P407
P577
2007-09-01T00:00:00Z